BioShares Biotechnology Valuation

BioShares Biotechnology Products -- USA Etf  

USD 40.65  0.64  1.56%

BioShares Biotechnology shows prevailing Real Value of $39.5 per share. The current price of the entity is $40.65. At this time the entity appears to be over valued. Macroaxis approximates value of BioShares Biotechnology from analyzing the entity fundamentals such as Three Year Return of 16.37%, Price to Earning of 18.03times and Price to Sales of 5.6times as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.
 Time Horizon     30 Days    Login   to change
BioShares Biotechnology Products is the top ETF in equity positions weight as compared to similar ETFs. It is third largest ETF in price to earning as compared to similar ETFs reporting about  0.18  of Price to Earning per Equity Positions Weight. The ratio of Equity Positions Weight to Price to Earning for BioShares Biotechnology Products is roughly  5.55 
Over Valued
January 20, 2018
Market Value
Downside upside
Real Value
Target Price Odds
 Above  Below  
Upside upside
BioShares Biotechnology is not too risky asset. Calculation of real value of BioShares Biotechnology is based on 1 month time horizon. Increasing BioShares Biotechnology time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.

Net Asset

BioShares Biotechnology Net Asset Analysis
BioShares Biotechnology Products is rated below average in net asset as compared to similar ETFs. Total Asset Under Management (AUM) of Health category is currently estimated at about 42.35 Billion. BioShares Biotechnology adds roughly 38.48 Million in net asset claiming only tiny portion of all ETFs under Health category.